sulopenem etzadroxil + probenecid

**Sulopenem etzadroxil + probenecid** is an oral fixed-dose antibacterial combination marketed in the United States as **Orlynvah**. Sulopenem etzadroxil is an orally absorbed penem prodrug that is converted to sulopenem, a beta-lactam antibacterial that binds bacterial penicillin-binding proteins and inhibits cell-wall synthesis. Probenecid inhibits renal organic anion transporter-mediated clearance of sulopenem, increasing systemic sulopenem exposure. The product is FDA-approved for uncomplicated urinary tract infections caused by susceptible *Escherichia coli*, *Klebsiella pneumoniae*, or *Proteus mirabilis* in adult women with limited or no alternative oral antibacterial options. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213972s000lbl.pdf))

Brand names

Orlynvah

Other names

oral sulopenemPF-03709270/probenecidsulopenem etzadroxil and probenecidsulopenem etzadroxil/probenecidsulopenem-etzadroxil/probenecid